GlassScriptPhysician profile
Kanchi Patell
NPI 1538782511
$3,153.35
in general payments reported to CMS, 2019-2025
28 companies · $996 in 2025
The $996 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.14 · 2021: $11.99 · 2022: $51.58 · 2023: $808 · 2024: $1,269 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.70 |
| Education | $288.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $416.35 | 2022-2025 | Fruzaqla, Ninlaro, Iclusig |
| Seagen INC. | $343.14 | 2023-2025 | Tukysa |
| Pfizer INC. | $329.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $290.21 | 2023-2024 | Lynparza, Calquence, Tagrisso |
| Janssen Biotech, INC. | $217.73 | 2025 | Carvykti, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $197.01 | 2023-2024 | Opdivo |
| Beone Medicines USA, INC. | $167.71 | 2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $145.56 | 2024 | |
| Merck Sharp & Dohme LLC | $139.25 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Beigene USA, INC. | $125.00 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $106.60 | 2024-2025 | Ojjaara |
| Abbvie INC. | $88.87 | 2024-2025 | |
| Celgene Corporation | $70.39 | 2024-2025 | Reblozyl |
| Tempus Ai, INC | $69.70 | 2024 | |
| Daiichi Sankyo INC. | $66.07 | 2024-2025 | Enhertu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $55.38 | 2022-2024 | |
| Amgen INC. | $48.46 | 2023 | Lumakras, Xgeva, Vectibix |
| Genmab U.S., INC. | $46.25 | 2023-2024 | Epkinly, Tivdak |
| Genzyme Corporation | $45.85 | 2025 | |
| Janssen Pharmaceuticals, INC | $29.13 | 2020-2021 | |
| Astellas Pharma US INC | $25.04 | 2024 | Vyloy |
| Aveo Pharmaceuticals, INC. | $23.06 | 2025 | |
| Gilead Sciences, INC. | $19.98 | 2024 | |
| Incyte Corporation | $19.81 | 2024 | Jakafi |
| Genentech USA, INC. | $18.69 | 2023 | Tecentriq, Alecensa |
| Adc Therapeutics America, INC. | $18.50 | 2024 | |
| Array Biopharma INC | $15.33 | 2024 | Braftovi, Lorbrena, Mektovi |
| Rigel Pharmaceuticals, INC. | $14.84 | 2025 | Gavreto, Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanchi Patell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.